Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose (Q40316729)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 29 July 2011

Language	Label	Description	Also known as
English	Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose	scientific article published on 29 July 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

tetanus vaccine

1 reference

based on heuristic

inferred from title

pertussis vaccine

1 reference

based on heuristic

inferred from title

Shelly A McNeil

object named as

Shelly McNeil

2

0 references

Joanne M. Langley

object named as

Joanne Langley

3

0 references

Scott A Halperin

1

object named as

Scott A Halperin

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

Mark Blatter

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Marc Dionne

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Joanne Embree

6

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Roehl Johnson

7

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Thomas Latiolais

8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

William Meekison

9

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Francisco Noya

10

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Shelly Senders

11

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Paul Zickler

12

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

David R Johnson

13

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

0 references

publication date

29 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

8459-8465

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Changing epidemiology and emerging risk groups for pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Pertussis infection in the United States: role for vaccination of adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Canadian experience with implementation of an acellular pertussis vaccine booster-dose program in adolescents: implications for the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

The present and future control of pertussis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix™) is immunogenic and well tolerated in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in a

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

[Allergic and non-allergic hypersensitivity reactions to toxoid-containing vaccines]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Outbreak of atypical pertussis detected by polymerase chain reaction in immunized preschool-aged children.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Seroprevalence of Pertussis in the Netherlands: Evidence for Increased Circulation of Bordetella pertussis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Investigation on a pertussis outbreak in a military school: risk factors and approach to vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Outbreak of Bordetella pertussis among oncology nurse specialists

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Duration of immunity against pertussis after natural infection or vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a french area with very high whole-cell vaccine coverage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Pertussis of adults and infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.068

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.07.068

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40316729&oldid=1895033784"